Last reviewed 2026-04-19 · How we verify

EN41-FPA2 HIV vaccine

PX'Therapeutics · Phase 1 active Biologic

EN41-FPA2 HIV vaccine is a Biologic drug developed by PX'Therapeutics. It is currently in Phase 1 development.

At a glance

Generic name	EN41-FPA2 HIV vaccine
Sponsor	PX'Therapeutics
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EN41-FPA2 HIV vaccine CI brief — competitive landscape report
EN41-FPA2 HIV vaccine updates RSS · CI watch RSS
PX'Therapeutics portfolio CI

Frequently asked questions about EN41-FPA2 HIV vaccine

What is EN41-FPA2 HIV vaccine?

EN41-FPA2 HIV vaccine is a Biologic drug developed by PX'Therapeutics.

Who makes EN41-FPA2 HIV vaccine?

EN41-FPA2 HIV vaccine is developed by PX'Therapeutics (see full PX'Therapeutics pipeline at /company/px-therapeutics).

What development phase is EN41-FPA2 HIV vaccine in?

EN41-FPA2 HIV vaccine is in Phase 1.

Manufacturer: PX'Therapeutics — full pipeline
Compare: EN41-FPA2 HIV vaccine vs similar drugs
Pricing: EN41-FPA2 HIV vaccine cost, discount & access